Related Experiment Videos
The short child. A matter of time or cause for concern?
Insights
Short stature often stems from non-endocrine causes like chronic illness or genetics. True endocrine-related short stature, including growth hormone deficiency, is rare but may be treatable with new therapies.
Area of Science:
- Pediatrics
- Endocrinology
- Genetics
Background:
- Short stature is a common concern in pediatric care.
- While often attributed to endocrine issues, non-endocrine causes are more prevalent.
Observation:
- Chronic systemic diseases, genetic factors, constitutional delay, and intrauterine influences can all impede growth.
- True endocrine causes are less common and include thyroid or adrenal disorders, growth hormone deficiency, and psychosocial dwarfism.
Findings:
- Growth hormone deficiency, though rare, is gaining attention.
- Recombinant DNA technology enables human growth hormone production, improving therapy availability.
Implications:
- New therapies offer hope for patients with confirmed growth hormone deficiency.
- Careful patient selection is crucial to avoid overuse of growth hormone therapy.
Abstract:
Short stature is less likely to have an endocrine basis than is commonly thought. Any of a number of chronic systemic diseases can slow growth, short stature may result from a genetic tendency or disorder, growth may be constitutionally delayed, or it may be retarded by intrauterine influences. True endocrine causes include thyroid or adrenal disorder, growth hormone deficiency, and psychosocial dwarfism. Although growth hormone deficiency is quite rare, it has received increased attention recently. The capability to produce human growth hormone by recombinant DNA techniques presents the prospect that replacement therapy will be more readily available to those patients who might benefit from it. Caution is called for, however, in making use of this agent for patients other than those with proven growth hormone deficiency.